IVF INVO Fertility Inc Forecast, Technical & Fundamental Analysis
INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need... Show more
IVF is expected to report earnings to fall 285.71% to -64 cents per share on November 23
Q3'26
Est.
$-0.65
Q2'26
Beat
by $1.05
The last earnings report on August 17 showed earnings per share of 34 cents, beating the estimate of -69 cents. With 255.76K shares outstanding, the current market capitalization sits at 2.66M.
A.I.dvisor indicates that over the last year, IVF has been closely correlated with INBS. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if IVF jumps, then INBS could also see price increases.
The 10-day RSI Oscillator for IVF moved out of overbought territory on August 18, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
IVF moved below its 50-day moving average on August 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IVF broke above its upper Bollinger Band on August 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IVF entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on IVF as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IVF just turned positive on August 03, 2026. Looking at past instances where IVF's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IVF advanced for three days, in of 197 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.165) is normal, around the industry mean (11.035). P/E Ratio (0.003) is within average values for comparable stocks, (70.949). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.006). IVF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.148) is also within normal values, averaging (34.463).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
